Business
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s
About this update from Biogen Inc.
[{"type":"text","content":"Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop oral macrocyclic peptides for priority targets in immunological conditions. Macrocyclic peptides have a unique profile with the potential to offer biologic-like efficacy and safety in an oral format, potentially disrupting established antibody-based treatments. The collaboration enhances Biogen’s strategy to build a differentiated immunology portfolio. Oral macrocyclic peptides are a promising class of medicines that can be orally administered but also have the potential for higher specificity and can target protein binding sites that are currently challenging for traditional small molecule drugs. Biogen and Dayra will collaborate to identify, validate and optimize oral macrocycle candidates for high-priority immunological targets, and Biogen will advance the molecules through further development and potential commercialization, including manufacturing. “With this collaboration, we are adding another potential best-in-class approach to our early-stage portfolio to target multiple high-value immunological conditions,” said Jane Grogan, Ph.D., Executive Vice President and Head of Research at Biogen. “Building on multiple technical advances in the field, we believe Dayra Therapeutics’ state-of-the-art macrocycle discovery platform could help realize the full potential of macrocycle-based treatments.” “This agreement with Biogen marks an important milestone as we advance our next generation oral macrocyclic peptides against clinically validated immunological targets,” said Rami Hannoush, Ph.D., venture partner at Versant Ventures and Dayra’s acting CEO. “With Biogen’s expertise and deep commitment to developing new treatment options for immunological conditions, we look forward to working together to unlock the potential of this innovative class of medicines.” Under the terms of the agreement, Dayra Therapeutics will receive a $50 million upfro...